Cytosorbents (CTSO) AI Stock Analysis

• Market Cap: $42.71M
• Dividend Yield: N/A
• Average Volume (3M): 134.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -8.97%
• EPS Growth: 47.29%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 62,804,306
• 10 Day Avg. Volume: 163,660
• 30 Day Avg. Volume: 134,354
• PEG Ratio: 0.06
• Price to Book (P/B): 4.46
• Price to Sales (P/S): 1.39
• P/FCF Ratio: -3.37
• Enterprise Value/Market Cap: 1.84
• Enterprise Value/Revenue: 2.17
• Enterprise Value/Gross Profit: 2.92
• Enterprise Value/Ebitda: -4.74
• 1Y Price Target: $0.75
• Price Target Upside: 5.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.64 ▼(-10.42% Downside)

Cytosorbents' overall stock score is primarily impacted by its challenging financial performance, characterized by high leverage and negative cash flows. The technical analysis indicates a bearish trend, while the valuation is unattractive due to ongoing losses. The earnings call provides some optimism with strategic initiatives, but risks remain, particularly with the Nasdaq compliance issue.

Positive Factors

Revenue Growth

The 10% revenue growth indicates a positive trend in sales, suggesting increased market penetration and product adoption, which is vital for long-term business sustainability.

Gross Margin Improvement

Improved gross margins reflect efficient cost management and production processes, enhancing profitability potential and financial health over time.

Regulatory Progress

Progress with FDA submissions can lead to new product approvals, expanding market opportunities and driving future revenue growth.

Negative Factors

High Leverage

High leverage increases financial risk, potentially limiting the company's ability to invest in growth opportunities and impacting long-term stability.

Negative Cash Flow

Negative cash flow poses liquidity challenges, affecting the company's ability to fund operations and invest in future growth, threatening financial sustainability.

Nasdaq Non-Compliance

Non-compliance with Nasdaq requirements risks delisting, which could reduce investor confidence and limit access to capital markets.

Cytosorbents Business Overview & Revenue Model

Company Description

Cytosorbents Corporation (CTSO) is a biomedical company focused on developing innovative therapies for critical care and other medical applications. The company specializes in blood purification technologies, primarily through its flagship product, CytoSorb, which is designed to remove cytokines and other harmful substances from the bloodstream. Cytosorbents operates in the healthcare sector, targeting hospitals and medical facilities with its advanced technologies aimed at improving patient outcomes in conditions such as sepsis, trauma, and cardiac surgery.

How the Company Makes Money

Cytosorbents generates revenue primarily through the sale of its medical devices, particularly the CytoSorb blood purification technology. The company sells its products directly to hospitals and healthcare systems, often through distribution agreements and partnerships with medical device distributors. Additionally, Cytosorbents may receive revenue from product consumables, including single-use cartridges that are essential for the operation of their devices. The company also engages in clinical studies and research collaborations, which can provide funding and enhance product validation, contributing to its overall revenue. Significant partnerships with healthcare providers and participation in various clinical trials help bolster its market presence and drive sales, especially in critical care settings where its products can provide significant therapeutic benefits.

Cytosorbents Financial Statement Overview

Summary

Cytosorbents faces significant financial challenges with consistent losses and high leverage. Despite strong gross profit margins, profitability is hindered by high operating expenses and negative cash flows, posing liquidity risks.

Income Statement

Cytosorbents has shown a slight improvement in revenue growth with a TTM growth rate of 2.37%. However, the company continues to face significant profitability challenges, as indicated by negative net profit and EBIT margins. The gross profit margin remains strong at 72.57%, suggesting efficient cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's balance sheet reflects high leverage with a debt-to-equity ratio of 2.34, indicating a reliance on debt financing. The return on equity is negative, highlighting ongoing losses. The equity ratio stands at 24.14%, suggesting a moderate level of equity financing relative to total assets, but the high debt levels pose a risk to financial stability.

Cash Flow

Cytosorbents is experiencing negative operating and free cash flows, with a declining free cash flow growth rate of -24.67% in the TTM period. The operating cash flow to net income ratio is close to 1, indicating that cash flow generation is in line with net losses, but the overall cash flow situation remains weak, posing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.11M	35.59M	31.08M	34.69M	40.11M	39.45M
Gross Profit	26.92M	25.13M	21.95M	20.73M	29.06M	28.40M
EBITDA	-16.57M	-15.22M	-27.88M	-30.00M	-21.62M	-9.71M
Net Income	-9.75M	-20.72M	-29.25M	-32.81M	-24.56M	-7.84M
Balance Sheet
Total Assets	47.99M	47.37M	53.26M	63.23M	89.52M	89.95M
Cash, Cash Equivalents and Short-Term Investments	10.20M	3.28M	14.13M	22.14M	52.14M	71.42M
Total Debt	27.06M	26.89M	18.31M	18.25M	13.82M	1.03M
Total Liabilities	36.40M	36.26M	29.99M	27.86M	26.94M	10.73M
Stockholders Equity	11.59M	11.11M	23.28M	35.37M	62.58M	79.22M
Cash Flow
Free Cash Flow	-10.29M	-14.71M	-22.59M	-34.69M	-18.29M	-7.29M
Operating Cash Flow	-9.78M	-14.43M	-21.66M	-28.23M	-14.01M	-5.61M
Investing Cash Flow	-601.55K	-669.43K	-936.24K	-6.46M	-4.28M	-1.68M
Financing Cash Flow	6.90M	9.33M	14.47M	4.96M	715.20K	66.35M

Cytosorbents Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Negative. The current price of 0.71 is above the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.74, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.71 is Neutral, neither overbought nor oversold. The STOCH value of 54.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTSO.

Cytosorbents Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ECOR	55 Neutral	$39.58M	-2.76	-337.84%	―	27.90%	1.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ICCM	45 Neutral	$45.65M	-2.60	-157.91%	―	-18.96%	8.98%
MDAI	45 Neutral	$43.58M	-1.90	―	―	-15.02%	-11.06%
CTSO	44 Neutral	$42.71M	-3.58	-96.15%	―	-8.97%	47.29%
TELA	44 Neutral	$50.76M	-1.29	―	―	12.24%	47.45%

Cytosorbents Corporate Events

Cytosorbents Faces Nasdaq Non-Compliance Notice

On October 2, 2025, CytoSorbents Corporation received a notice from Nasdaq for non-compliance with the Minimum Bid Price Requirement, as its stock price remained below $1.00 for 30 consecutive business days. The company has until March 31, 2026, to regain compliance by ensuring its stock price meets or exceeds $1.00 for at least 10 consecutive days. Failure to comply could lead to an additional compliance period if an acceptable plan is presented to Nasdaq. The company is actively monitoring its stock price and exploring options to meet the requirement.